About ORM / Orosomucoid:
Orosomucoid, also known as alpha-1-acid glycoprotein (AGP), was first reported in 1950. It is an acute-phase protein produced in the liver as well as in extrahepatic sites. Due to acute inflammation, it can cause the plasma concentrations of ORM levels to rapidly increase in response. Plasma levels are affected by burns, certain drugs, pregnancy, HIV, and other certain diseases.
Orosomucoid-related receptors have been initially explored in liver parenchymal cells, macrophages, and neutrophils. Respectively involving the membrane septro CCR5, HBB and Siglec-5. ORM can act as a disease marker, carry and bind drugs, modulate immunity, mediating the sphingolipid metabolism, and maintain the carrier function of the capillary.
Because there is not a concrete known function for orosomucoid, it is of the opinion that orosomucoid (ORM) regulates the immune system in the acute-phase reaction. It's also suggested that ORM is part of a negative feedback system. The production of ORM by leukocytes can be stimulated by inflammatory cytokines (like interleukin 1 and tumor necrosis factor-a).
Orosomucoid (ORM) is part of the acute-phase proteins. It is heavily glycosylated at 45% with a molecular weight of 37-54 kDa and a low pl of 2.8-3.8. The liver is the primary production of ORM. But under various physiological and pathological conditions, it was reported that many extrahepatic tissues can produce ORM. A combination of the significant regulator go-between, like IL-6, IL-1, glucocorticoids, and TNF-a, can control aspects of the ORM gene.